comparemela.com

Latest Breaking News On - David zaccardelli - Page 3 : comparemela.com

Verona Pharma Announces the US FDA has Accepted the New Drug Application Filing for Ensifentrine for the Maintenance Treatment of COPD

Verona Pharma Announces the US FDA has Accepted the New Drug Application Filing for Ensifentrine for the Maintenance Treatment of COPD
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United-kingdom
London
City-of
Leslie-humbel
David-zaccardelli
Verona-pharma
International-us-media-enquiries
Drug-administration
Nasdaq
Company-new-drug-application
Action-date
New-drug-application

Verona Pharma plc (NASDAQ:VRNA) Shares Bought by Affinity Asset Advisors LLC

Affinity Asset Advisors LLC increased its position in shares of Verona Pharma plc (NASDAQ:VRNA – Free Report) by 8.5% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 452,821 shares of the company’s stock after acquiring an additional 35,323 shares during the quarter. Verona […]

Kathleena-rickard
David-zaccardelli
Verona-pharma
Tucker-asset-management
Tower-research-capital
Goldman-sachs-group-inc
Nasdaq
Exchange-commission
Sg-americas-securities
Affinity-asset-advisors
Canaccord-genuity-group
Free-report

Verona Pharma plc (NASDAQ:VRNA) Shares Acquired by Affinity Asset Advisors LLC

Affinity Asset Advisors LLC raised its position in shares of Verona Pharma plc (NASDAQ:VRNA – Free Report) by 8.5% in the first quarter, according to its most recent filing with the SEC. The firm owned 452,821 shares of the company’s stock after purchasing an additional 35,323 shares during the quarter. Verona Pharma makes up approximately […]

David-zaccardelli
Kathleena-rickard
Verona-pharma
Securities-exchange-commission
Tower-research-capital
Tucker-asset-management
Goldman-sachs-group-inc
Nasdaq
Canaccord-genuity-group
Affinity-asset-advisors
Sg-americas-securities
Free-report

Verona Pharma (NASDAQ:VRNA) Earns "Buy" Rating from Canaccord Genuity Group

Canaccord Genuity Group reaffirmed their buy rating on shares of Verona Pharma (NASDAQ:VRNA – Free Report) in a research report released on Friday morning, Benzinga reports. They currently have a $35.00 target price on the stock. A number of other equities research analysts have also recently commented on VRNA. 500.com reaffirmed a reiterates rating on […]

Verona-pharma
David-zaccardelli
Jennison-associates
Carlyle-group-inc
Securities-exchange-commission
Canaccord-genuity-group
Free-report
Truist-financial
Pharma-stock-down
Get-free-report
General-counsel-claire-poll
Exchange-commission

Verona Pharma (NASDAQ:VRNA) Stock Price Up 4.6%

Shares of Verona Pharma plc (NASDAQ:VRNA – Get Free Report) rose 4.6% during trading on Monday . The stock traded as high as $19.06 and last traded at $19.04. Approximately 88,910 shares changed hands during trading, a decline of 82% from the average daily volume of 500,320 shares. The stock had previously closed at $18.20. […]

Verona-pharma
Markw-hahn
David-zaccardelli
Goldman-sachs-group-inc
Tower-research-capital
Sg-americas-securities
Nasdaq
Verona-pharma-company-profile
Tucker-asset-management
Get-free-report
Asset-management
Sachs-group

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.